Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 6, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate in two upcoming
View HTML
Toggle Summary Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments
MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 5, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced it has granted an exclusive worldwide license to develop and
View HTML
Toggle Summary Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
MONROVIA, Calif. --(BUSINESS WIRE)--Jan. 8, 2020-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a technology
View HTML
Toggle Summary Xencor Appoints Dagmar Rosa-Bjorkeson to Board of Directors
MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 20, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Dagmar
View HTML
Toggle Summary Xencor Appoints Allen Yang, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 18, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Allen Yang ,
View HTML
Toggle Summary Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting
-- Live webcast to review initial clinical data at 8:30 p.m. EST tonight -- MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 9, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic
View HTML
Toggle Summary Xencor to Present at Upcoming Investor Conferences
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 13, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will
View HTML
Toggle Summary Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that initial data from its ongoing
View HTML
Toggle Summary Xencor Reports Third Quarter 2019 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET today -- MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 5, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic
View HTML
Toggle Summary Xencor to Host Third Quarter 2019 Financial Results Webcast and Conference Call on November 5, 2019
MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 29, 2019-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release third quarter
View HTML